| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | SCHEDULE 13G |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Financial Statements and Exhibits
Received authorization in the United Kingdom and European Union to expand global first-in-human ASCEND Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1-related disorder, adding to clearances in Australia and Argentina |
| 05 Nov 2026 | SCHEDULE 13G/A |
| 28 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
On September 28, 2026, CAMP4 Therapeutics Corporation (the “Company”) held an Analyst Day meeting regarding its planned Phase 1/2 ASCEND clinical trial of CMP-002 in SYNGAP1-related disorder (the “ASCEND clinical trial”) and its pipeline... |
| 02 Sep 2026 |
Form 4: Gold Kelly, Chief Financial Officer
Bought 10,000 shares ($39.6K) |
| 31 Aug 2026 | SCHEDULE 13D/A |
| 31 Aug 2026 |
Form 4: Schwab Andrew J., Director
Sold 400,000 shares ($1.62M) |
| 26 Aug 2026 |
Form 4: Schwab Andrew J., Director
Sold 10 shares ($45) |
| 21 Aug 2026 |
Form 4: Schwab Andrew J., Director
Sold 45,147 shares ($215K) · Sold 114,700 shares ($521K) · Sold 32,018 shares ($144K) |
| 19 Aug 2026 |
Form 4: Tardiff Daniel, Chief Scientific Officer
Sold 1,738 shares ($8.27K) |
| 19 Aug 2026 | SCHEDULE 13D/A |
| 19 Aug 2026 | 144 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth quarter of this year. |
| 12 Aug 2026 | EFFECT |
| 12 Aug 2026 | 424B3 |
Loading...